These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 2303102)

  • 1. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO).
    Johnson CS; Cook CA; Furmanski P
    Exp Hematol; 1990 Feb; 18(2):109-13. PubMed ID: 2303102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative regulators of in vivo erythropoiesis: interaction of IL-1 alpha and TNF-alpha and the lack of a strict requirement for T or NK cells for their activity.
    Johnson CS; Pourbohloul SC; Furmanski P
    Exp Hematol; 1991 Feb; 19(2):101-5. PubMed ID: 1991491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of erythropoiesis and myelopoiesis by exogenous erythropoietin in human long-term marrow cultures.
    Mayani H; Guilbert LJ; Janowska-Wieczorek A
    Exp Hematol; 1990 Mar; 18(3):174-9. PubMed ID: 2303109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cadmium on in vitro and in vivo erythropoiesis: erythroid progenitor cells (CFU-E), iron, and erythropoietin in cadmium-induced iron deficiency anemia.
    Sakata S; Iwami K; Enoki Y; Kohzuki H; Shimizu S; Matsuda M; Moriyama T
    Exp Hematol; 1988 Aug; 16(7):581-7. PubMed ID: 3391251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal erythroid cell production during erythropoietin treatment of mice occurs by exploiting the splenic microenvironment.
    Nijhof W; Goris H; Dontje B; Dresz J; Loeffler M
    Exp Hematol; 1993 Apr; 21(4):496-501. PubMed ID: 8462658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha.
    Tsopra OA; Ziros PG; Lagadinou ED; Symeonidis A; Kouraklis-Symeonidis A; Thanopoulou E; Angelopoulou MK; Vassilakopoulos TP; Pangalis GA; Zoumbos NC
    Acta Haematol; 2009; 121(4):187-95. PubMed ID: 19468203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor exerts dose-dependent effects on erythropoiesis and myelopoiesis in vivo.
    Ulich TR; del Castillo J; Yin S
    Exp Hematol; 1990 May; 18(4):311-5. PubMed ID: 2323367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy.
    de Haan G; Engel C; Dontje B; Loeffler M; Nijhof W
    Cancer Res; 1995 Jan; 55(2):324-9. PubMed ID: 7529132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice.
    Otsuki T; Nagakura S; Wang J; Bloom M; Grompe M; Liu JM
    J Cell Physiol; 1999 Apr; 179(1):79-86. PubMed ID: 10082135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-12 directly enhances in vitro murine erythropoiesis in combination with IL-4 and stem cell factor.
    Dybedal I; Larsen S; Jacobsen SE
    J Immunol; 1995 May; 154(10):4950-5. PubMed ID: 7537295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible role of tumor necrosis factor-alpha in erythropoietic suppression by endotoxin and granulocyte/macrophage colony-stimulating factor.
    Udupa KB; Sharma BG
    Am J Hematol; 1996 Jul; 52(3):178-83. PubMed ID: 8756083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect in vitro of tumor necrosis factor-alpha (TNF) on normal and virus-infected erythroid progenitors from Friend virus (FVA)-infected mice.
    Chang MJ; Pourbohloul SC; Yu WD; Furmanski P; Johnson CS
    Exp Hematol; 1992 Dec; 20(11):1271-7. PubMed ID: 1337323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The erythropoietic effects of interleukin 6 and erythropoietin in vivo.
    Ulich TR; del Castillo J; Yin SM; Egrie JC
    Exp Hematol; 1991 Jan; 19(1):29-34. PubMed ID: 1989892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
    Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
    J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tumor necrosis factor-alpha on normal feline hematopoietic progenitor cells.
    Khan KN; Kociba GJ; Wellman ML; Reiter JA
    Exp Hematol; 1992 Aug; 20(7):900-3. PubMed ID: 1321052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
    Wisniewski D; Strife A; Atzpodien J; Clarkson BD
    Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo.
    Clibon U; Bonewald L; Caro J; Roodman GD
    Exp Hematol; 1990 Jun; 18(5):438-41. PubMed ID: 2338132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development.
    Wang CQ; Udupa KB; Lipschitz DA
    J Cell Physiol; 1995 Jan; 162(1):134-8. PubMed ID: 7814445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor.
    Chen J; Jacobs-Helber SM; Barber DL; Sawyer ST
    Exp Cell Res; 2004 Aug; 298(1):155-66. PubMed ID: 15242770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.